istock-956478432_patricia-dallaire
Patricia-Dallaire / iStockphoto.com
31 May 2018AsiaArchana Shanker and Nupur Maithani

Uncertain times for antibodies in India

Subject matter patentability and sufficiency requirements are issues that are dealt with at the Indian Patent Office (IPO). Issues/challenges relating to these aspects often go unnoticed unless there is an opposition involved. Here we are writing about trends in India in relation to antibodies. The increase in investment in research in the fields of biotechnology and antibodies, in particular, has led to an increase in filing of patent applications related to antibodies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
6 January 2026   Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.
Asia
9 December 2025   The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.
Asia
4 December 2025   The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.